Pharming Group

#5918

Rank

$1.08B

Marketcap

Netherlands

Country

Leadership team

Mr. Jeroen Wakkerman (Chief Financial Officer)

Dr. Sijmen de Vries M.B.A., M.D., MBA (Pres, CEO & Exec. Director)

Dr. Bruno M. L. Giannetti (Consultant)

Products/ Services

Biotechnology, Health Care

Number of Employees

100 - 500

Headquarters

Leiden, Zuid-Holland, The Netherlands

Established

1988

Company Registration

SEC CIK number: 0001828316

Net Income

20M - 100M

Revenue

100M - 500M

Traded as

PHAR

Social Media

URL

https://www.pharming.com

Overview

Location

Recognition and Award

References

Summary

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

History

Pharming Group was founded in 1998 and incorporated in 2000. The company focuses on the research, development and commercialization of novel therapies and rare disease treatments. The company has a broad portfolio of innovative products and services, including recombinant human enzymes, recombinant human proteins, plasma-derived proteins and the development of several orphan drugs. Pharming is engaged in the development of innovative products and services to serve the medical needs of patients.

Mission

Our mission is to develop and bring to market transformative therapies for patients and healthcare professionals that address unmet needs and improve patient care.

Vision

Our vision is to be a leading global player in the development, production and commercialization of innovative and transformative rarity cures and services to enhance patient care.

Key Team

Ms. Mireille Sanders M.Sc. (Chief Operations Officer)

Susanne Embleton (Investor Relations Mang.)

Mr. Ruud Van Outersterp (Chief Ethics & Compliance Officer)

Mr. Anurag Relan (Chief Medical Officer)

Mr. Stephen Toor (Chief Commercial Officer & GM of Americas)

Recognition and Awards

Pharming has been awarded the European Biotechnology Excellence Award and the International Food and Drug Regulatory Science Award for its contributions to medicine and biotechnology. The company has also been the recipient of numerous awards for its commitment to ethical leadership, including being named one of the top 50 most ethical companies in Europe by The Financial Times and EP Vantage.